Learn about the effectiveness of tumor-targeted T cell immunotherapy from our patients.
This is a treatment result comparison between two groups of patients.
The value of CD3+, CD3+CD4+, CD4+/CD8+ and NK (Natural Killer) cells in peripheral blood significantly increased after a combination treatment including dendritic cells immunotherapy (DC therapy), comparing with patients who did not have DC therapy. Read more
This comparison report shows that the activated T cells are significantly increased, and the Regulatory T cells significantly declined after the cancer treatment, which means this patient’s immune system can kill more cancer cells in the body. This is a study on a patient with colorectal cancer. Read more
Mr. Chu is a 58 years old Chinese male with diagnosis of colon cancer.
In November 2007, at the outer line of sigmoid colon cancer resection, he was given after four cycles of Eloxatin and Xeloda chemotherapy. In February 2008, Mr. Chu prompted to relapse by colonoscopy, with second surgery at a cancer hospital in Shanghai, after surgery revealed no metastasis, the original course of chemotherapy continued for six weeks. Read more
Mr. Zhao, 51 years old male from China. Four years ago, he was diagnosed with prostate cancer with multi-metastasis to bone. His PSA value kept rising up to as high as 940.9. He never had an effective treatment until he received the DC-CTL cancer immunotherapy (dendritic cell and T cell based). During the treatment with immunotherapy, he did not have any other treatment at the same time. Read more
Xiao Jian is a 25 years old young man from an ordinary family in Anhui province. In the summer of 2012, symptoms like coughing, fever, chest discomfort or breathing difficulties occasionally happened to him. Xiao Jiang thought they were caused by catching a cold until one day he was hard to breathe after playing a short while in a basketball game. He tried several times, but he could never play for over an hour, which was so easy for him in the past. What was wrong with Xiao Jian? Read more